Ozempic is not just good for people with type 2 diabetes, it’s one of the most effective treatments available. The FDA has approved it specifically to improve blood sugar control in adults with type 2 diabetes, and clinical trials consistently show it lowers A1C by 1.2 to 1.8 percentage points, a substantial drop that can move many people from poorly controlled diabetes into their target range. Beyond blood sugar, Ozempic also carries FDA approval for reducing the risk of heart attack, stroke, and cardiovascular death in diabetic patients with established heart disease, and for slowing kidney disease progression.
How Ozempic Works in the Body
Ozempic mimics a natural hormone called GLP-1 that your gut releases after eating. This hormone does several things at once: it signals your pancreas to produce more insulin when blood sugar is high, it tells your liver to stop releasing stored sugar into your bloodstream, and it slows the speed at which food leaves your stomach. That last effect means glucose enters your blood more gradually after meals, preventing the sharp spikes that make diabetes harder to manage.
Because the drug only triggers insulin release when blood sugar is elevated, the risk of dangerously low blood sugar (hypoglycemia) is much lower than with older diabetes medications like sulfonylureas or insulin. This makes Ozempic a safer daily option for many people.
Blood Sugar Results From Clinical Trials
Ozempic was tested across a large series of clinical trials called the SUSTAIN program, which compared it to other diabetes treatments and placebo. The A1C reductions were consistent and significant across all trials. At the standard 0.5 mg dose, A1C dropped by 1.2 to 1.5 percentage points. At the higher 1.0 mg dose, reductions ranged from 1.5 to 1.8 points. These results held whether patients were using Ozempic alone, alongside metformin, or added on top of insulin.
To put that in practical terms, if your A1C is 8.5%, a 1.5-point reduction brings you to 7.0%, which is the general target most guidelines recommend. For many people, that shift means fewer diabetes complications over the long term, including less damage to nerves, eyes, and kidneys.
Heart and Kidney Protection
Type 2 diabetes significantly raises the risk of heart attack, stroke, and kidney failure. Ozempic has proven benefits for both.
A major trial called FLOW studied over 3,500 people with type 2 diabetes and chronic kidney disease across 28 countries. Participants who received Ozempic had a 24% lower rate of cardiovascular death, 18% fewer major cardiovascular events, and 20% fewer deaths from any cause compared to placebo. Their kidney function also declined more slowly, with a meaningful difference in the rate of filtration loss year over year. Notably, fewer people in the Ozempic group experienced serious side effects than in the placebo group (49.6% vs. 53.8%).
These findings are a big part of why the 2025 American Diabetes Association Standards of Care now recommend GLP-1 medications like Ozempic for people with type 2 diabetes and chronic kidney disease, specifically to protect the heart and slow kidney damage. The ADA also recommends considering GLP-1 medications for diabetic patients with obesity and heart failure, and for those with fatty liver disease linked to metabolic dysfunction.
Weight Loss as a Bonus
Although Ozempic is prescribed at lower doses for diabetes than for obesity, it still produces meaningful weight loss. In studies, participants using GLP-1 medications lost an average of 10% to 15% of their body weight over a year. Even a 5% to 10% reduction improves metabolic health, lowers blood pressure, and reduces the risk of conditions like fatty liver disease and sleep apnea. For people managing both type 2 diabetes and excess weight, this dual benefit is a major advantage over older diabetes drugs, some of which cause weight gain.
Common Side Effects
The most frequently reported side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. These affect more than 5% of patients. The good news is that most of these symptoms occur during the dose escalation phase, when your body is still adjusting to the medication, and they tend to improve over time.
Only about 3% to 4% of patients in clinical trials discontinued Ozempic because of GI side effects, which means the vast majority tolerate it well enough to stay on treatment. Higher doses do cause more GI issues: roughly 34% of patients on the 2 mg dose reported gastrointestinal symptoms compared to about 31% on the 1 mg dose.
How Dosing Works
Ozempic is a once-weekly injection, which many people prefer over daily medications. Your doctor will start you at 0.25 mg per week for the first four weeks. This starting dose isn’t meant to control blood sugar; it lets your body adjust to the drug and reduces the likelihood of nausea. After four weeks, the dose increases to 0.5 mg. From there, your doctor may increase to 1 mg or eventually 2 mg depending on your blood sugar response and how well you tolerate the medication. For patients who also have chronic kidney disease, increasing from 0.5 mg to 1 mg is specifically recommended after at least four weeks.
Who Should Not Take Ozempic
Ozempic carries a boxed warning related to thyroid tumors. It is not safe for anyone with a personal or family history of medullary thyroid carcinoma, or for people with a rare condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated for anyone who has had a serious allergic reaction to semaglutide.
Ozempic is approved only for type 2 diabetes, not type 1. People with type 1 diabetes do not produce insulin on their own, and Ozempic’s mechanism of boosting insulin release in response to high blood sugar requires functioning insulin-producing cells to work.